Imatinib is a substrate for hOCT1 (SLC22A1) and inhibitors of this influx transporter, such as amantadine and prazosin, have previously been shown to decrease cellular imatinib uptake. However, here we report that in longer term experiments, both drugs paradoxically increase the cytotoxicity of all three currently licensed tyrosine kinase inhibitors (TKIs), imatinib, nilotinib and dasatinib. This effect is due to release of intracellular calcium from the endoplasmic reticulum (ER), with changes in mitochondrial calcium and alterations in mitochondrial membrane permeability, resulting in caspase-mediated apoptosis. The effect is confined to BCR-ABL-positive cells, and is greater in primary cells than in cell lines. Furthermore, in primary cells at original diagnosis, the effect is only seen in samples from patients destined to become complete cytogenetic responders to imatinib. These results indicate that calcium release from the ER, here induced by amantadine or prazosin, may prime BCR-ABL-positive cells to TKI-induced apoptosis. Amantadine/prazosin primed TKI cytotoxicity in vitro may be a useful test for the level of ER-releasable calcium, and may be of prognostic value.
Introduction
Imatinib is a tyrosine kinase inhibitor (TKI) that is now in widespread use as first-line therapy of chronic myeloid leukaemia (CML). However, it is increasingly clear that at least a third of imatinib-treated patients may become resistant, and an additional proportion may become intolerant. This has led to the development of the second-generation TKIs, nilotinib and dasatinib. Nilotinib is a more selective inhibitor of the ABL kinase with approximately 25-fold increased potency relative to imatinib. 1 It has significant activity in patients resistant to or intolerant of imatinib. 2, 3 Dasatinib inhibits both the ABL and SRC kinase families and has also been shown to be efficacious. [4] [5] [6] However, there is currently no evidence that any of these agents achieve cure.
The endoplasmic reticulum (ER) is a vital intracellular calcium store and is also responsible for protein synthesis, posttranslational modifications and transport. Alterations of calcium homeostasis in the ER result in ER stress and consequently affect protein synthesis and transport. [7] [8] [9] [10] Rises in both cytosolic and mitochondrial calcium have been reported in several cell types to lead to apoptosis. [11] [12] [13] [14] [15] BCR-ABL expression has been reported to modulate calcium homeostasis in the ER, and interfere with ER-mediated apoptotic pathways to promote survival of CML cells. 16 Changes in either the prevailing ER calcium levels and/or resultant calcium influx into the ER (known as capacitative calcium entry (CCE)) may compromise calcium-dependent apoptotic mechanisms in BCR-ABL-expressing cells. 16 Treatment of BCR-ABL-positive cells with imatinib restored ER calcium levels and induced apoptosis. 16 Furthermore, imatinib has also been reported to induce cell death in a gastrointestinal stromal tumour cell line 17 and in murine myeloid progenitors transduced with BCR-ABL through an ER-mediated stress response. 18 In the course of investigations of how one TKI modifies the transport of another, we observed by chance that amantadine and prazosin primed CML cells for TKI-mediated cytotoxicity. Here, we explore this effect, and demonstrate that it is mediated through a rise in cytosolic calcium concentrations resulting both from membrane influx and ER release, and that this results in a change in mitochondrial membrane permeability leading to apoptosis. We also report that in primary cells at original diagnosis, this effect is confined to samples from patients destined to respond to imatinib.
Materials and methods

Reagents
Amantadine, prazosin, digitonin, sulfinpyrazone, ionomycin, ethidium bromide (EtBr-), ethylene glycol tetraacetic acid (EGTA), fura 2-acetoxy methyl ester (fura 2-AM) and Rhod 2-acetoxy methyl ester (Rhod 2-AM), the cell-permeable pan-caspase inhibitor, N-benzyloxycarbonyl-Val-Ala-Asp(O-Me)-FMK (Z-VAD-FMK) and inhibitors of caspases 3, 8 and 9, respectively;
and Z-LE (OMe)HD(OMe)-FMK (Z-LEHD-FMK) were purchased from Sigma-Aldrich (Poole, Dorset, UK). Roswell Park Memorial Institute medium (RPMI-1640) was from Biosera (East Sussex, UK), the antibiotics penicillin and streptomycin were from Invitrogen Life Technologies (Paisley, Scotland, UK). Annexin V-fluorescein isothiocyanate apoptosis detection kit was purchased from Clontech Laboratories (Saint Germain en Laye, France) and the MTT Cell Proliferation Assay was from LGC Promochem/ATCC (Middlesex, UK). Imatinib and nilotinib were kind gifts from Novartis (Basel, Switzerland). Dasatinib was a kind gift from Bristol-Myers Squibb Pharmaceuticals (New York, NY, USA).
Cell lines, primary cells and cell culture
Four BCR-ABL-positive leukaemic cell lines KYO1, LAMA84, KCL22 and K562 were utilised for the experiments. The cell lines were a kind donation from the Leukaemia Unit, Hammersmith Hospital London, UK. Primary CML cells were isolated by leukapheresis from eight CML patients and stored in liquid nitrogen. All patients gave informed consent, and the study was approved by the Liverpool Research Ethics Committee. When required, the cells were thawed an hour before use for experiments. All cell lines and primary cells were maintained at a density of 2 Â 10 6 cells/ml in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum, 1% L-glutamine, 1% penicillin and 1% streptomycin (henceforth referred to as RPMI complete medium) at 37 1C in a humidified 5% CO 2 incubator throughout the experiment. For intracellular and mitochondrial calcium measurements, 1 Â 10 7 cells/ml were resuspended in a HEPES-buffered saline solution containing 125 mM NaCl, 5 mM KCl, 1 mM MgSO 4 , 1mM Na 2 -HPO 4 , 5.5 mM glucose, 5 mM NaHCO 3 , 1mM CaCl 2 and 20 mM HEPES (pH 7.4).
Apoptosis measurement
Apoptosis was measured using the annexin V-fluorescein isothiocyanate apoptosis detection kit (Clontech Laboratories), according to the manufacturer's recommendations. Briefly, 4 Â 10 5 cells were collected post treatment with or without varying concentrations of TKIs in the presence or absence of either amantadine or prazosin. Cells were then washed once with the binding buffer, and stained with 5 ml fluorescein isothiocyanate-conjugated annexin V antibody in 195 ml binding buffer. The reaction was carried out at room temperature for 15 min and applied to the FACScan in a final volume of 500 ml immediately after staining with 10 ml of 50 mg/ml propidium iodide. Following acquisition, cells that were negative for both propidium iodide and annexin V were categorised as being viable, and these data used to determine the total cell viability.
Cell proliferation
Cell proliferation was measured using the 3-4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide (MTT) colourimetric reduction method, as described by the manufacturer (LGC Promochem/ATCC). Briefly, 100 ml of 2 Â 10 6 /ml TKI-treated and -untreated cells in the presence or absence of either 500 mM amantadine or 20 mM prazosin were added to 96-well plates in quadruplicates and incubated in RPMI complete medium for 45 min-48 h at 37 1C in a humidified 5% CO 2 atmosphere. At the end of incubation time, 10 ml of MTT reagent was added to each of the 96-well plates, followed by incubation in the dark for 3 h at 37 1C. After 3 h, the cells were lysed overnight in 100 ml of lysis buffer, and absorbance measured at 570 nm in a Spectra max Plus microplate reader (Molecular Devices, Ismaning, Germany).
Measurement of free intracellular calcium concentration
Changes in free intracellular calcium concentration were measured with the fluorescent indicator fura 2-AM using an Aminco Bowman Series 2 Spectrofluorometer (Thermo Electron, Middlewich, Cheshire, UK). In some of the experiments, in order to measure calcium release from the intracellular stores, calcium chloride (CaCl 2 ) was omitted from the extracellular buffer, and instead 0.5 mM EGTA added (Ca 2 þ -free buffer solution). Calibration of maximum fluorescence (F max ) and minimum fluorescence (F min ) was performed after each run by adding 25 mM digitonin followed by 50 mM EGTA. Briefly, cells (1 Â 10 7 /ml) were washed in phosphate-buffered saline and resuspended in HEPES-buffered saline solution, in the presence of 4 mM fura 2-AM and 250 mM sulfinpyrazone. Incubation was performed at 37 1C for 15 min. Cells were then washed in the same solution and changes in free intracellular calcium concentration were determined in a 37 1C temperaturecontrolled magnetically stirred cuvette using the 340/380 excitation ratio and an emission wavelength of 505 nm. The calcium ionophore ionomycin (100 nM) was added at the end of each time course as an internal assay control. 
Changes in plasma membrane permeability
Changes in plasma membrane permeability were measured by monitoring the uptake of the dye EtBr. Briefly, 5 Â 10 5 cells/ml were kept in a magnetically stirred fluorometric cuvette, with the thermostat at 37 1C, and incubated in the presence of 20 mM EtBr-. To achieve complete permeabilisation of the cells, 100 mM digitonin was added at the end of the experiment (100% fluorescence signal). Fluorescence was measured at an excitation wavelength of 360 nm; emission was 580 nm.
Measurement of mitochondrial calcium changes
To measure changes in mitochondrial calcium, cells were loaded with Rhod 2-AM (4 mM) in HEPES-buffered saline solution for 40 min at 37 1C. Cells were then washed and re-suspended in calcium-free buffer solution. Fluorescence was measured over time using a spectrofluorometer at excitation and emission wavelengths of 550 nm and 580 nm, respectively. Thapsigargin was used as a positive control for mitochondrial calcium variations.
Measurement of mitochondrial membrane potential (MMP)
To evaluate changes in MMP, treated and untreated cells (4 Â 10 5 /ml) were incubated with 3,3 0 -dihexyloxacarbocyanine iodide (DiOC6) (40 nM in phosphate-buffered saline; Molecular Probes, Invitrogen, Paisley, Scotland, UK) for 20 min at 37 1C, followed by the addition of 10 ml of 50 mg/ml propidium iodide, to assess cell viability. Analysis was carried out on a cytofluorometer at excitation and emission wavelengths of 488 nm and 525 nm, respectively.
Statistical analyses
Data are expressed as mean ± s.e.m. All experiments were carried out at least three times. Comparisons were made using the paired Student's t-test. P-values o0.05 were accepted as being significant.
Results
Interaction between amantadine and prazosin with TKIs on CML cell lines
The BCR-ABL-positive cell lines LAMA 84, KYO-1, K562 and KCL22 were screened to determine their sensitivity to dasatinib, nilotinib and imatinib. The rank order of sensitivity was LAMA-844KYO-14K5624KCL22 (data not shown). A time-course experiment was then performed on the most sensitive cell line (LAMA84), using optimal concentrations of TKIs at which maximum cell death was observed (imatinib 1 mM, nilotinib 0.02 mM or dasatinib 0.02 mM). Adding a 30-min pre-incubation with either amantadine (500 mM) or prazosin (20 mM) had minimal effects on cell viability after TKI for 45 min or 24 h; however, this amantadine or prazosin priming significantly increased TKI-mediated cell death after 48-h incubation (Supplementary Figures 1A and B, respectively) . Similar results were observed on TKI-mediated anti-proliferative effect (Supplementary Figures 1C and D, respectively) . These concentrations of amantadine and prazosin were chosen because at these concentrations, both drugs have a significant inhibitory effect on human organic cation transporter 1 (hOCT1; SLC22A1) at shorter time points. Figures 1a-f show the anti-proliferative and apoptotic effects respectively, following 48-h TKI treatment in the presence or absence of amantadine or prazosin priming. Similar results were observed in the other BCR-ABL-positive cell lines; although no effect was seen in normal peripheral blood mononuclear cells (data not shown).
The effects of amantadine and prazosin priming on TKIinduced cytotoxicity were also assessed in KYO-1, K562 and KCL22. In all three cell lines, priming with amantadine or prazosin for 30 min before TKI treatment for 48 h significantly decreased cell viability, with the least effect in the most resistant cell type ( KCL22) (Figures 1g-i) .
Interaction between amantadine/prazosin and TKIs in primary CML cells
The effect of amantadine and prazosin priming was assessed in primary cells from eight CML patients at original diagnosis before any treatment. Clinical details are reported in Supplementary Table 1 . Within 12 months of imatinib treatment, five of these patients achieved complete cytogenetic response (CCR, defined as none of at least 20 metaphases positive for the Philadelphia chromosome at 12 months), and three patients did not achieve CCR at this stage (two of whom had bone marrow transplants at 12 and 13 months). In samples from all five responding patients, priming with amantadine or prazosin for 30 min before TKI treatment for 48 h significantly decreased cell viability (Figure 2a) . Conversely, no such effect of priming was seen at 48 h in any of the three patients who failed to achieve CCR (Figure 2b ). Figure 2c shows the response in two nonresponders following 72-h treatment. The in vitro sensitivity to any of the TKIs following either amantadine or prazosin pretreatment is therefore related to the clinical response to imatinib treatment. Interestingly, in cytogenetically responding patients, amantadine or prazosin alone both decreased cell viability (Figure 2a) , an effect not seen in cell lines or in samples from cytogenetic non-responders (Figure 2b ).
Effects of amantadine and prazosin on intracellular calcium changes BCR-ABL expression confers a deficiency in a calciumdependent apoptotic pathway, 16 while amantadine modulates intracellular calcium mobilisation 20 and improves cell membrane permeability. 21 We therefore investigated whether amantadine and prazosin pre-treatment was acting via an effect on intracellular calcium. 1 Â 10 7 cells/ml were loaded with 4 mM fura 2-AM and 250 mM sulfinpyrazone in HEPES-buffered saline solution and changes in free intracellular Ca 2 þ concentration were monitored with a spectrofluorometer. Ionomycin (100 nM) was added at the end of each time course as an internal assay control. To measure calcium release from intracellular stores, 0.5 mM EGTA was added to the buffer and CaCl 2 was omitted. At this concentration and time course, EGTA did not affect cell viability. Both amantadine and prazosin caused an immediate increase in calcium influx across the cell membrane (Figures 3a  and b , trace labelled a) and calcium release from the intracellular stores (trace labelled b). The response to added calcium in Figure 3c is compatible with CCE and suggests that the ER is a possible target for both drugs. To investigate this further, the ER calcium release agent thapsigargin (2 mM) was used as a positive control. This completely blocked amantadine (Figure 3d , trace a) but not prazosin (Figure 3d , trace b) mediated calcium release. In addition, amantadine significantly decreased the amount of thapsigargin induced ER-calcium release (Figure 3e , trace a), while this was completely blocked by prazosin (Figure 3e, trace b) ; confirming that both amantadine and prazosin cause release of calcium from the ER. Pretreatment with prazosin (but not amantadine) for 5 min before adding TKI significantly increased the basal calcium concentration from 54±6.84 to 524±7.65 nM (Po0.001) (Figure 3f ). These data suggest that prazosin but not amantadine may also be having an effect on membrane calcium permeability.
Effects of amantadine and prazosin on plasma membrane permeability
To assess whether prazosin (but not amantadine) has a direct effect on cell membrane permeability, the impermeant membrane dye EtBr-was used. Complete permeabilisation of the cells was achieved by adding 100 mM digitonin at the end of each experiment. Prazosin but not amantadine caused a significant increase in cell membrane permeability as compared with control cells (Po0.000001; Figure 4a ). Furthermore, preincubation with prazosin but not amantadine for as short as 5 min before TKI addition significantly increased the basal membrane permeability to EtBr-from 1.72 to 2.23, 2.24 and 2.24, respectively (P-values o0.000001; Figure 4a ). Figures 4b-c are representative of EtBr-fluorescence following the addition of either prazosin, amantadine or digitonin (positive control). These data confirm an effect of prazosin, but not of amantadine, on cell membrane permeability.
Effects of amantadine and prazosin on mitochondrial calcium changes
As calcium is released from the ER into the cytoplasm, the mitochondria take up part of the released calcium to dampen the effect of a sudden large rise in intracellular calcium concentration. [22] [23] [24] The effect of amantadine and prazosin on mitochondrial calcium concentrations was therefore assessed using Rhod 2-AM, a mitochondrial calcium fluorescent indicator. Thapsigargin, which causes sustained ER calcium release and therefore induces mitochondrial calcium uptake, was used as a positive control. Figure 5 shows that amantadine, prazosin and thapsigargin all cause an increase in mitochondrial calcium uptake.
A key event in early apoptosis is permeabilisation of the mitochondrial membrane. Sufficient and sustained ER calcium release, supported by CCE and calcium influx, has to occur to induce mitochondrial calcium overload and loss of MMP. 25 The effects of amantadine and prazosin on MMP were therefore examined. Cells (4 Â 10 5 /ml) were incubated with DiOC6 for 20 min at 37 1C, followed by propidium iodide staining to assess cell viability. Figure 6a shows that pre-treatment of LAMA-84 cells for 1 h with either amantadine or prazosin causes a nonsignificant increase (hyper-polarisation) of MMP (Figures 6a  and b) . However, at 24 h (when no significant cell death is observed), both amantadine and prazosin cause significant depolarisation of the mitochondrial membrane (Figures 6a and c) . In Figure 6 , panels (b and c) are representative of DiOC6 fluorescence at 1-h and 24-h treatment, respectively, corresponding to the histograms in panel (a).
Implications of calcium and caspases on amantadine/ prazosin and TKI effects
To further investigate the intracellular calcium concentration rises mediated by amantadine and prazosin, the membrane Calcium release primes TKI-induced apoptosis SL Forchap et al Z-VAD-FMK-AM (100 mM) protected cells from the effect of prazosin and TKI (Figures 7d-f) . Co-application of Z-VAD-FMK-AM with BAPTA-AM provided additional cellular protection (Figures 7a-f) , although cell death was not completely prevented. Together, these data suggest that calcium and caspases are critical for the cytotoxic effects mediated by either amantadine or prazosin in combination with TKIs.
To investigate the effect of specific caspases, the membrane permeable irreversible caspase inhibitors for caspases 3, 8 and 9 (Z-DEVD-FMK, Z-IETD-FMK and Z-LEHD-FMK, respectively) were used. Cell death induced by either amantadine or prazosin and TKIs was not attenuated following pre-treatment for 30 min with any of these inhibitors used in isolation ( Supplementary  Figures 2A and B) . Co-application of any of these with 10 mM BAPTA-AM significantly attenuated amantadine or prazosin/TKImediated cell death. These data indicate that the cytotoxic effect mediated by either amantadine or prazosin in combination with TKIs is dependent on the activation of a caspase combination rather than a single caspase.
Discussion
The present work arose from a chance observation with amantadine and prazosin, during an investigation of TKI transport mechanisms in CML cells. These drugs are known to block the uptake transporter hOCT1, which we previously showed to be important in imatinib uptake in short-term experiments (o4 h). 26 These drugs would therefore be expected to decrease imatinib-induced cell death by blocking imatinib uptake. Here, however, we demonstrate that each drug has the opposite effect over a longer time course; pre-treatment by each before 48-h incubation with any of the three TKIs increased their anti-proliferative and apoptotic effects in BCR-ABL-positive cells. This effect was not seen in normal cells. Previous studies investigating imatinib uptake by hOCT1 using inhibitors such as amantadine and prazosin have incubated the drugs for o4 h. Thus, the effects we have in our longer term incubations are unlikely to be dependent on hOCT1 expression. This is further emphasised by the fact that similar effects were witnessed with both nilotinib and dasatinib, which are not primarily transported by hOCT1. 27, 28 The present work has four salient findings. First, in primary cells from newly diagnosed patients, the priming effect of amantadine/prazosin on TKI is only seen in samples from patients destined to achieve CCR after 12 months of imatinib treatment; no effect is seen in patients who become cytogenetic non-responders. This suggests that the priming effect of amantadine and prazosin may be useful prognostically. Second, both drugs cause a prompt rise in intracellular calcium level, because of release from the ER, with an increase in CCE and calcium influx. Pre-treatment with prazosin before the addition of TKIs significantly increased cell membrane permeability and the basal calcium concentration. These observations have not been previously reported for BCR-ABLpositive cells. It has been well established in a range of cell types that the ER is the major intracellular calcium store required for induction of apoptosis. BCR-ABL expression modulates ER calcium homeostasis, leading to interference with ER-mediated apoptotic pathways and thereby promoting cell survival, and this effect on ER-releasable calcium is greater than that on CCE. 16 Decreasing ER calcium concentration may increase HeLa cell survival in response to oxidant stress induced by ceramide. 29 Double knockout Bax and Bak (pro-apoptotic proteins) mouse fibroblasts displayed a reduced resting ER calcium concentration compared with wild-type cells, and were resistant to induction of apoptosis. 30 These data suggest that the ER calcium concentration is an important determinant of cellular susceptibility to apoptotic stimuli. 16, 29, 30 Third, we show that both amantadine and prazosin induce an increase in mitochondrial calcium uptake, and also altered MMP. Calcium release from the ER into the cytoplasm causes the mitochondria to take up part of the released calcium, thus preventing the propagation of large calcium waves. [22] [23] [24] This influx is followed by calcium efflux from the mitochondria back into the cytosol. 31, 32 It has been suggested that sufficient and sustained ER calcium release, supported by CCE and calcium influx, is necessary to induce a calcium overload and loss of MMP in the mitochondria. 25 When mitochondria are exposed to a pathological overload of calcium, opening of the mitochondrial permeability transition pore is triggered, which is a key event in early apoptosis. The exact mechanism through which this process occurs is unclear, but may involve cyclophilin D 33 and a voltage-dependent anion channel. 34 Finally, the effect of amantadine/prazosin induced cell death was attenuated by BAPTA-AM or by Z-VAD-FMK-AM. This demonstrates that the effect is dependent on the release of intracellular calcium, and on caspases. Use of specific caspase inhibitors demonstrates that calcium-dependent activation of caspases 3, 8 or 9 is crucial for this effect.
Taken together, these results suggest that cytosolic calcium increase is responsible for amantadine/prazosin primed TKI cytotoxicity in BCR-ABL-positive cells. BCR-ABL expression has been reported to reduce the free ER-releasable calcium concentration, leading to cell survival. 16 Amantadine is licensed as an anti-viral agent and for use in Parkinson's disease; prazosin is an alpha-1 adrenoreceptor blocker and has been recently reported to have efficacy in prostate cancer cells. 35 We do not believe that either drug has clinical potential to augment the effect of TKI, since we show that they have reduced sensitivity in patients destined to fail imatinib, and the concentrations used were supra-therapeutic. However, their in vitro effect appears to be a surrogate for the degree of ER-releasable calcium, and it is plausible that this may be related to the level of BCR-ABL protein. Their effect on primary cells at diagnosis may therefore give useful prognostic information. However, more patient samples are needed to explore these findings. In addition, it would be useful to develop more potent analogues of amantadine and prazosin or modulators of intracellular/ER calcium, which are active at therapeutically relevant concentrations. The findings highlight a novel Achilles heel of the BCR-ABL-positive cell; prospective studies pegged to clinical trials are required to investigate this further.
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